The new changes to the “Sunshine Act” has left people more confused than ever in regard to information needing to be submitted, what payments are supposed to be submitted and the entire reporting format. Andy McNeill, (AMI, CEO) who has a wealth of experience in the pharmaceutical meeting planning industry, with clients such as Baxter, Pfizer and Roche, elaborates on the changes and how they will affect meeting planners in the future.
Relationships and Community Service Brings Award to Event Industry Professional
Recently AMI, American Meetings Inc. own Chelsea Litos was recognized as one of the 40 Under 40 Young Professionals of South Florida. Ms…
